Sort
10,766 grants matching “checkpoint inhibitor”
Polyamine blockade and anti-tumor immunity in head and neck squamous cell carcinoma
$170,208Richard Alexander Harbison · Washington University · K08 · FY2025 · DE
The prognostic landscape of gender- and ethnicity-specific immune influences on cancer outcomes
$170,194Andrew J. Gentles · Stanford University · R21 · FY2019 · CA
Project 1: 5FU and Vitamin D as Neoadjuvants for Photodynamic Priming to Enhance Skin Cancer Therapy
$170,143Edward V. Maytin · Massachusetts General Hospital · P01 · FY2024 · CA
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung Cancer
$170,089Jessy Satyadas Deshane · University Of Alabama At Birmingham · R21 · FY2023 · CA
Hematologic Malignancies
$169,872Ronald Levy · Stanford University · P30 · FY2025 · CA
Protection of kidney from autoimmunity by modulating co-stimlatory signaling
$169,860Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2019 · DK
IMMUNE CHECKPOINT BLOCKADE PROMOTES ADULT T CELL LEUKEMIA
$169,786Lee Ratner · Washington University · R21 · FY2019 · CA
Unraveling myeloid-mediated mechanisms of immunotherapy resistance in prostate cancer bone metastases at single-cell resolution
$169,776Aram Lyu · Fred Hutchinson Cancer Center · K99 · FY2025 · CA
Regulation of Genomic Instability in Early Breast Cancer
$169,701Thea D Tlsty · University Of California, San Francisco · R01 · FY2007 · CA
Exploring potential biomarkers predictive of response to ATR and CHK1 inhibitors
$169,650Junran Zhang · Ohio State University · R21 · FY2018 · CA
Targeting metabolism in leukemic stem cells
$169,650Cheng-Kui Qu · Emory University · R21 · FY2014 · CA
Targeting Tryptophan Dioxygenase Degradation for Suppression of Tumor Immune Evasion
$169,589Ryan A Altman · Purdue University · R21 · FY2023 · CA
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer
$169,563Samuel Lai · Univ Of North Carolina Chapel Hill · R21 · FY2024 · CA
Development of a new treatment modality for melanoma brain metastases - Resubmission - 1
$169,500Iman Osman · New York University School Of Medicine · R21 · FY2016 · CA
Modulation of CD8+ T cell differentiation and anti-tumor immunity by metabolic manipulation
$169,500Geoffrey Joseph Markowitz · Weill Medical Coll Of Cornell Univ · R03 · FY2024 · TR
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$169,500Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2020 · CA
TARGETING THE SHEDDING OF TRANSMEMBRANE PD-L1 TO ENHANCE THERAPEUTIC EFFICACY OF IMMUNE CHECKPOINT INHIBITORS
$169,499Icahn School Of Medicine At Mount Sinai · · FY2021 · Department of the Army
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$169,406Sheng Tong · Rice University · R01 · FY2019 · EB
Core B: Biological Models, Multiplexed Optical Biopsy, Molecular Pathology, and Biostatistics Core
$169,322Bryan Quilty Spring · Massachusetts General Hospital · P01 · FY2024 · CA
Role of FAT1 somatic mutations in aggressiveness of head and neck cancer
$169,248Yong Teng · Emory University · R03 · FY2022 · DE
Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma
$169,233Souvik Banerjee · Middle Tennessee State University · R16 · FY2025 · GM
Core 2: Glioblastoma Biorepository Core
$169,138Keith L Ligon · Brigham And Women'S Hospital · P01 · FY2022 · CA
Mitotic Regulation by the ERRbeta2 Splice Variant
$169,106Rebecca B Riggins · Georgetown University · R21 · FY2014 · CA
Development of high throughput assays to identify small molecule inhibitors of th
$169,000Pengbo Zhou · Weill Medical Coll Of Cornell Univ · R21 · FY2011 · NS
In vivo anti-PD1 gene therapy
$168,970Andre Michael Lieber · University Of Washington · R21 · FY2018 · CA